INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board

Transparency directive : regulatory news

05/05/2011 19:23

PRESS RELEASE

                  APPOINTMENT OF CATHERINE MOUKHEIBIR TO THE
                      EXECUTIVE BOARD OF INNATE PHARMA

Marseilles, France, May 5, 2011

Innate Pharma (the "Company" - Euronext Paris: FR0010331421 - IPH) announces
today the reinforcement of its management with the appointment of Catherine
Moukheibir to its Executive board, as Senior Advisor Finance.

Catherine Moukheibir, MA, MBA (from Yale University), will be in charge of the
financial strategy of the Company. She has 16 years of experience in finance
including 10 in the biotechnology industry. Prior to joining Innate Pharma, Mrs
Moukheibir was CFO of Movetis, a Belgian biotech company (from 2008 to 2010),
for which she led the IPO on Euronext Brussels and then the acquisition by
Shire. Previously, she was Director Capital Markets at Zeltia (from 2001 to
2007), a Spanish biopharma and consumer chemicals group, where she led
financial strategy. Before joining Zeltia, she was Executive Director
Investment Banking with Salomon Smith Barney and Morgan Stanley (from 1997 to
2000).

"We are very happy to welcome Catherine Moukheibir to our team. She brings
extensive experience in our sector, from both the industry and banking
perspectives. She also knows very well the investor community, in Europe as
well as in the United States, and we hope that she will contribute to expand
Innate Pharma's visibility through the realignment of its history and
perspectives", said Hervé Brailly, CEO of Innate Pharma.

About Innate Pharma:

Innate Pharma S.A. is a biopharmaceutical company developing first-in-class
immunotherapy drugs for cancer and inflammatory diseases.
The Company specializes in the development of new monoclonal antibodies
targeting receptors and pathways controlling the activation of innate immunity
cells. Its most advanced drug-candidate is IPH 2101, an anti-KIR monoclonal
antibody potentiating NK cells activation currently in Phase II clinical trials
in hematologic cancers. Two of its antibody programs in chronic inflammation
are out-licensed to Novo Nordisk A/S.

Innate Pharma's key expertise is in immunopharmacology and antibody technology.
The Company has implemented in-house a large panel of molecular and cellular
assays and in vivo models for assessing the pharmacodynamics and
pharmacotoxicology of drug candidates. In addition, Innate Pharma has access
to a very large set of unique research tools in cellular immunology through
its worldwide network of scientific collaborations.

Incorporated in 1999 and listed on NYSE-Euronext in Paris in 2006, Innate
Pharma is based in Marseilles, France, and had 85 employees as at
March 31, 2011.

Learn more about Innate Pharma at www.innate-pharma.com.

Practical Information about Innate Pharma shares:

ISIN code            FR0010331421
Ticker code          IPH

Disclaimer:
This press release contains certain forward-looking statements. Although the
company believes its expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and uncertainties,
which could cause actual results to differ materially from those anticipated.
For a discussion of risks and uncertainties which could cause the company's
actual results, financial condition, performance or achievements to differ
from those contained in the forward-looking statements, please refer to the
Risk Factors ("Facteurs de Risque") section of the Document de Reference
prospectus filed with the AMF, which is available on the AMF website
(http://www.amf-france.org) or on Innate Pharma's website.

This press release and the information contained herein do not constitute an
offer to sell or a solicitation of an offer to buy or subscribe to shares in
Innate Pharma in any country.

For additional information, please contact:

Innate Pharma                        Alize Public Relations
Laure-Hélène Mercier                 Caroline Carmagnol
Director, Investor Relations         Phone: +33 (0)1 41 22 07 31
Phone: +33 (0)4 30 30 30 87          Mobile: +33 (0)6 64 18 99 59
investors@innate-pharma.com          caroline@alizerp.com

IPH_Catherine Moukheibir

INNATE PHARMA's latest news

05/04/2024 09:34

INNATE PHARMA (EPA:IPH) Innate Pharma (Euronext Paris: FR0010331421 – IPH) announces today the reinforcement of its management with the appointment of Catherine Moukheibir to its Executive board

Transparency directive : regulatory news

INNATE PHARMA's latest news

Other stories